BOEHRINGER INGELHEIM NEXGARD SPECTRA 3'TABLETS

Boehringer Ingelheim, a global leader in animal health, announced the launch of NexGard SPECTRA (afoxolaner and milbemycin oxime) in India, following its approval by the Central Drugs Standard Control Organisation (CDSCO). After the successful launches of its blockbuster NexGard range of products - NexGard X and L in 2020 and NexGard S and M (afoxolaner) in 2023, this represents an expansion of the NexGard product line for dogs aged between two months and weighing two kgs and above.

NexGard SPECTRA is a soft, flavourful chew for dogs that offers broad-spectrum internal and external parasite control in a single monthly dose. As a prescription-only product in India, NexGard SPECTRA contains two active ingredients: afoxolaner, which targets fleas and ticks, and milbemycin oxime, which protects against heartworm and controls intestinal worms. NexGard SPECTRA provides comprehensive protection in a single monthly chewable, offering convenience, safety and peace of mind.

Parasites can lead to a range of health issues, from mild discomfort to life-threatening conditions, impacting the overall well-being of dogs. Fleas, ticks, and mites can cause skin irritation, and allergic reactions, and transmit diseases such as tick fever. Heartworms can lead to heart failure and lungworms can cause respiratory problems. While intestinal worms like roundworms, hookworms, tapeworms, and whipworms can result in gastrointestinal issues, anaemia, weight loss, and even fatalities, especially in young puppies.